Yes they have projected revenue figures in the relm of 500m. Which does correlate well with there estimated VU prevalence which is good because it shows consistancy.
Both relevant points.
I'm not overly concerned about approval based on the fact that the EMA brought forward post approval questions after resolving all pre approval questions which is where the crux of the issues for approval lie.
As far as market penetration goes if the same or similar results are acheived that were acheived in trials then this should not be to difficult, link follows for trial data. Its worth keeping in mind that the candidates used in the trials had previously not responded to at least 4 weaks of standard care which the company have previously stated was the best currently available treatment.
